The global menopausal therapy market size was estimated to be USD 17.54 billion in 2023 and is expected to reach at USD 33.57 billion by 2034 with a CAGR of 6.08% during the forecast period 2024-2034. Rising prevalence of post-menopausal symptoms, surge in sedentary lifestyle, increasing occurrence of vasomotor & menopausal symptoms including night sweats & hot flashes in women as they go through the menopausal transition, growing adoption of hormone replacement therapy for menopausal symptoms especially vasomotor symptoms, rising investment in the treatment of menopausal manifestation, surge in adoption of OTC products by patients, increasing launch of new medications, and growing mergers and acquisitions within key market players are some of the major factors propelling the market growth.
Growing mergers and acquisitions within key market players is predicted to boost the market growth during the forecast period. Menopause is a natural occurrence stemming from the aging of ovaries, resulting in reduced production of reproductive hormones, signifying the conclusion of reproductive years. It represents not only a biological transition but also a societal change that can be impacted by elements like gender roles, family interactions, and cultural views on aging and menopause within a woman's surroundings. Consequently, industry participants are prioritizing mergers and acquisitions as a strategy to broaden their range of products. For instance, in April 2022, Bonafide, a company focused on women's health products, with a specialization in over-the-counter offerings, has obtained the rights to a patented formulation of S-adenosylmethionine known as MSI-195.
By treatment, dietary supplements was the highest revenue-grossing segment in the global menopausal therapy market in 2023 owing to the rising investment in research & development activities, increasing shift towards natural & herbal products, and surge in new product launches by the key market players. Additionally, OTC pharma products is predicted to grow at fastest CAGR during the forecast period owing to the changing pattern among pharmaceutical companies where they are increasingly focusing on creating over-the-counter (OTC) products for addressing menopausal symptoms, rising adoption of hormonal therapy, growing launch of new products, and surge in number of product approvals. For instance, in May 2023, The U.S. Food and Drug Administration (FDA) has granted approval for Veozah (fezolinetant), an oral medication designed to address moderate to severe vasomotor symptoms, commonly known as hot flashes, resulting from menopause. Veozah marks the FDA's first approval of a neurokinin 3 (NK3) receptor antagonist for the treatment of moderate to severe menopausal hot flashes.
By distribution channel, retail pharmacies was the highest revenue-grossing segment in the global menopausal therapy market in 2023 owing to the rising preference for community pharmacies, surge in collaborations within market players. For instance, in September 2022, Boots has collaborated with GenM to introduce a new program aimed at helping women find suitable menopause-related products and services. They are introducing a 'Menopause Friendly' symbol, which will be visible both online and in physical stores, to indicate products and services that could potentially alleviate some menopausal signs and symptoms. This labeling system makes it convenient for customers to identify these specific products and services. Additionally, hospital pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of women’s population suffering from menopause and increasing trend in the prescription of medications and healthcare services for women going through menopause in hospital settings.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of Post- Menstrual Syndrome (PMS), growing awareness regarding women's health, surge in healthcare spending, increasing healthcare infrastructure, and rising partnerships & collaborations between market players. For instance, in October 2022, Amyris, Inc. has unveiled the introduction of two fresh brands within its expanding consumer lineup. One of these brands is Stripes, which focuses on (peri)menopausal wellness and was created in collaboration with actress, entrepreneur, and activist Naomi Watts. The second brand is EcoFabulous, a clean and sustainable beauty brand targeted at Gen-Z consumers, offering affordably priced high-quality color cosmetics and skincare products. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for menopausal therapy options, growing demand for non-hormonal therapy options for managing menopausal symptoms, presence of major market players, and surge in research & development activities. For instance, in August, 2022, Lupin Limited, a worldwide pharmaceutical company, has established an exclusive licensing agreement with the Japanese company l'rom Group Co., Ltd. This arrangement aims to conduct clinical trials for a biosimilar version of Denosumab in Japan. Denosumab is authorized for the treatment of osteoporosis in postmenopausal women at a high risk of fractures and for preventing skeletal-related events in patients with bone metastases from solid tumors.
Growing mergers and acquisitions within key market players is predicted to boost the market growth during the forecast period. Menopause is a natural occurrence stemming from the aging of ovaries, resulting in reduced production of reproductive hormones, signifying the conclusion of reproductive years. It represents not only a biological transition but also a societal change that can be impacted by elements like gender roles, family interactions, and cultural views on aging and menopause within a woman's surroundings. Consequently, industry participants are prioritizing mergers and acquisitions as a strategy to broaden their range of products. For instance, in April 2022, Bonafide, a company focused on women's health products, with a specialization in over-the-counter offerings, has obtained the rights to a patented formulation of S-adenosylmethionine known as MSI-195.
By treatment, dietary supplements was the highest revenue-grossing segment in the global menopausal therapy market in 2023 owing to the rising investment in research & development activities, increasing shift towards natural & herbal products, and surge in new product launches by the key market players. Additionally, OTC pharma products is predicted to grow at fastest CAGR during the forecast period owing to the changing pattern among pharmaceutical companies where they are increasingly focusing on creating over-the-counter (OTC) products for addressing menopausal symptoms, rising adoption of hormonal therapy, growing launch of new products, and surge in number of product approvals. For instance, in May 2023, The U.S. Food and Drug Administration (FDA) has granted approval for Veozah (fezolinetant), an oral medication designed to address moderate to severe vasomotor symptoms, commonly known as hot flashes, resulting from menopause. Veozah marks the FDA's first approval of a neurokinin 3 (NK3) receptor antagonist for the treatment of moderate to severe menopausal hot flashes.
By distribution channel, retail pharmacies was the highest revenue-grossing segment in the global menopausal therapy market in 2023 owing to the rising preference for community pharmacies, surge in collaborations within market players. For instance, in September 2022, Boots has collaborated with GenM to introduce a new program aimed at helping women find suitable menopause-related products and services. They are introducing a 'Menopause Friendly' symbol, which will be visible both online and in physical stores, to indicate products and services that could potentially alleviate some menopausal signs and symptoms. This labeling system makes it convenient for customers to identify these specific products and services. Additionally, hospital pharmacies is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of women’s population suffering from menopause and increasing trend in the prescription of medications and healthcare services for women going through menopause in hospital settings.
North America region is anticipated for the highest revenue share during the forecast period owing to the rising prevalence of Post- Menstrual Syndrome (PMS), growing awareness regarding women's health, surge in healthcare spending, increasing healthcare infrastructure, and rising partnerships & collaborations between market players. For instance, in October 2022, Amyris, Inc. has unveiled the introduction of two fresh brands within its expanding consumer lineup. One of these brands is Stripes, which focuses on (peri)menopausal wellness and was created in collaboration with actress, entrepreneur, and activist Naomi Watts. The second brand is EcoFabulous, a clean and sustainable beauty brand targeted at Gen-Z consumers, offering affordably priced high-quality color cosmetics and skincare products. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the increasing demand for menopausal therapy options, growing demand for non-hormonal therapy options for managing menopausal symptoms, presence of major market players, and surge in research & development activities. For instance, in August, 2022, Lupin Limited, a worldwide pharmaceutical company, has established an exclusive licensing agreement with the Japanese company l'rom Group Co., Ltd. This arrangement aims to conduct clinical trials for a biosimilar version of Denosumab in Japan. Denosumab is authorized for the treatment of osteoporosis in postmenopausal women at a high risk of fractures and for preventing skeletal-related events in patients with bone metastases from solid tumors.
Segmentation: Menopausal Therapy Market Report 2023 - 2034
Menopausal Therapy Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Bn)
- OTC Pharma Products
- Non-Hormonal Therapy
- Hormonal Therapy
- Dietary Supplements
Menopausal Therapy Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)
- Hospital Pharmacies
- E-Commerce Platform
- Retail Pharmacies
Menopausal Therapy Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Menopausal Therapy Market: Treatment Estimates & Trend Analysis
8. Menopausal Therapy Market: Distribution Channel Estimates & Trend Analysis
9. Regional Market Analysis
10. North America Menopausal Therapy Market
11. Europe Global Menopausal Therapy Market
12. Asia Pacific Global Menopausal Therapy Market
13. Latin America Global Menopausal Therapy Market
14. MEA Global Menopausal Therapy Market
15. Competitor Analysis
16. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Novo Nordisk A/S
- Abbott
- Pfizer Inc.
- Bayer AG
- Allergan
- Theramex
- Eli Lily and Company
- PADAGIS LLC
- Emcure Pharmaceuticals Ltd
- AbbVie Inc.
- Novartis AG
- Rainbow Light
- Cipla Inc.
- Dr. Reddy’s Laboratories Ltd.
- Teva Pharmaceuticals
- Pure Encapsulations LLC.
- Merck & Co. Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 17.54 Billion |
| Forecasted Market Value ( USD | $ 33.57 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 18 |
